Navigation Links
Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests
Date:7/28/2008

Roche will market the RAMP(R) cardiovascular product line in the United

States and Canada

INDIANAPOLIS, July 28 /PRNewswire/ -- Roche Diagnostics and Response Biomedical have entered into a partnership that will allow Roche to market the first line of cardiovascular tests for Response Biomedical's new point-of-care platform.

The platform, the RAMP(R) 200 (Rapid Analyte Measurement Platform), is based on RAMP technology that is already used in laboratories worldwide for West Nile Virus, biodefense tests and the recently FDA-cleared RAMP Flu A/B Test.

The RAMP cardiovascular product line includes Troponin-I, CK-MB, Myoglobin and NT-proBNP. Roche has exclusive rights to market the cardiovascular line in the United States, Canada and other global markets.

"Having the test menu at the patient's bedside may provide physicians with the improved 'vein-to-brain' time that is often critical when treating patients with potentially life-threatening cardiovascular conditions," said Rodney Cotton, Senior Vice President of Roche Diagnostics' Point of Care division. "The RAMP 200 will allow physicians to treat patients faster because it can help reduce the amount of time from when a patient presents with symptoms to when treatment begins."

The RAMP 200 cardiovascular line is expected to be launched in the first quarter of 2009. The test system uses whole blood and can perform 18 to 36 tests per hour. Up to six tests of all one type or a mixture of tests may be run simultaneously. Results appear in as little as 15 minutes.

The RAMP cardiac tests are simple to use and may be placed in a variety of hospital locations, which provides the hospital with more staffing flexibility, and reduces potential delays due to sample transportation and processing.

Guidelines from the American College of Cardiology and the American Heart Association require or recommend a patient presenting with a potential AMI (acute myocardial infarction, or heart attack) be diagnosed within 60 minutes, and preferably within 30 minutes.

"One of the advantages of this system for critical care is that all of the RAMP cardiac tests correlate to the same tests on larger analyzers in the lab, such as the cobas 6000 series," said Ken Levy, Director of Strategic Business Development for Roche Diagnostics' Point of Care division. "This way, physicians can be confident that the results they get in the ER and in the lab are consistent, so they can provide better treatment to the patient."

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested more than 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP Platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF." For further information, please visit the company's website at http://www.responsebio.com.

All trademarks used or mentioned in this release are legally protected by law.

For further information, please contact:

Media:

Lori McLaughlin

Corporate Communications

Roche Diagnostics Corporation

Indianapolis, Ind.

Phone: 317-521-3112

lori.mclaughlin@roche.com


'/>"/>
SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... WESTLAKE VILLAGE, Calif. , March 24, 2017 /PRNewswire/ ... medical dermatology and aesthetics company, today announced that ... Financial Officer, effective March 24.   Peterson, who ... will succeed John Smither , who is retiring ... serve Sienna in an advisory capacity. Peterson joins Sienna ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which is ... polymer exhibits properties to gently absorb compressive forces and return to its natural ...
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer ... input from industry experts to validate the ...
Breaking Biology Technology:
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
Breaking Biology News(10 mins):